Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL

Summary

Participants (N=10/group) will consist of non-treatment seeking individuals with AUD. Following informed consent and baseline screening, participants will partake in 3 stress induction sessions to assess their stress levels and cravings for alcohol. Participants will be randomized to receive either increasing doses of doxazosin XL (0, 4, and 8 mg) or placebo in a double-blind manner.

Timeline

Start

2022-05-12

Primary completion

2023-10-01

Completion

2023-10-01

Drugs

Indications